^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD-L1 inhibitor

    Related drugs:
    15h
    AUSTRAL: Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen (clinicaltrials.gov)
    P2, N=21, Recruiting, Mario Negri Institute for Pharmacological Research | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Imfinzi (durvalumab) • ceralasertib (AZD6738)
    18h
    Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Completed, Ascletis Pharmaceuticals Co., Ltd. | Recruiting --> Completed
    Trial completion
    |
    ASC61
    20h
    IMMUNOCELL: Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P=N/A, N=4, Terminated, Assistance Publique - Hôpitaux de Paris | N=120 --> 4 | Trial completion date: Sep 2027 --> Sep 2025 | Recruiting --> Terminated; Abandon of study
    Enrollment change • Trial completion date • Trial termination • IO biomarker
    |
    Tecentriq (atezolizumab)
    21h
    ALPACA: A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Bavencio (avelumab)
    1d
    Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial (clinicaltrials.gov)
    P1/2, N=63, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • etoposide IV
    1d
    Efficacy and safety of Atezolizumab plus Bevacizumab and Lenvatinib as first-line systemic therapies for hepatocellular carcinoma: A real-world study. (PubMed, PLoS One)
    In conclusion, the study demonstrates that ATEZO/BEV significantly improves OS compared to LEN in patients with unresectable HCC, despite similar PFS, ORR, and DCR. Both treatments have comparable safety profiles.
    Retrospective data • Journal • Real-world evidence
    |
    AFP (Alpha-fetoprotein)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Lenvima (lenvatinib)
    1d
    SKYSCRAPER-06: A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=542, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • pemetrexed • tiragolumab (RG6058)
    1d
    Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab. (PubMed, Liver Cancer)
    Additionally, ctDNA maxVAF demonstrated independent prognostic value in patients treated with first-line atezo/bev. Liquid biopsy using ctDNA can help address challenges associated with limited tissue-based genomic profiling in advanced HCC.
    Journal • PD(L)-1 Biomarker • IO biomarker • Circulating tumor DNA
    |
    Guardant360® CDx
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    1d
    A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2/3, N=990, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • pumitamig (BNT327)
    2d
    CEIL: Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=198, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Enweida (envafolimab)
    3d
    ABATE-MASLD: The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD (clinicaltrials.gov)
    P2/3, N=20, Recruiting, Eastern Hepatobiliary Surgery Hospital
    New P2/3 trial
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    3d
    SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC (clinicaltrials.gov)
    P2, N=208, Recruiting, Shandong Provincial Hospital
    New P2 trial
    |
    capecitabine • oxaliplatin • AiRuiLi (adebrelimab)